Zogenix Stock

Zogenix Equity

Delisted

The The Equity of Zogenix (ZGNX) as of Aug 6, 2026 is 178.97 M USD. In the previous year, The Equity was 369.67 M USD — a change of -51.59% (lower).

Equity

178.97 MUSD

YoY

-51.59%

Last updated:

In 2026, Zogenix's equity was 178.97 M USD, a -51.59% increase from the 369.67 M USD equity in the previous year.

Access this data via the Eulerpool API

Zogenix Stock analysis

What does Zogenix do? Zogenix Inc. is an American biotech company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. The company was founded in 2006 and is headquartered in Emeryville, California. In 2009, Zogenix Inc. brought its first product to market, the prescription painkiller Zohydro. Shortly after, in 2012, the company announced the approval of Sumavel DosePro, an innovative injection technology for the treatment of migraines. In 2018, the company completed a merger with California-based Modis Therapeutics. Together, they are developing drugs for rare genetic metabolic disorders. Zogenix has a promising business model, focusing on research and development and the marketing of true innovations in the CNS and pain field. The company aims to revolutionize the medical market with its medications, rather than simply replacing existing drugs. For this reason, Zogenix collaborates closely with leading institutes and research facilities to identify and develop new active ingredients. Zogenix is divided into various business segments, each specializing in the development of new drugs and therapies. One of Zogenix's main products is the Sumavel DosePro injection technology, which allows for quick and effective treatment of migraine attacks. Another important business area for Zogenix is the development of medications and therapies for the treatment of neuropsychiatric disorders. This includes ZX008 (Fenfluramine), an investigational drug for the treatment of Dravet syndrome, a rare form of epilepsy. The medication has already been approved in Europe and is currently being reviewed in the United States. Zogenix also focuses on the development of therapies for opioid and opiate-related disorders, as well as pain management. This includes the product Zohydro, which is a long-acting opioid painkiller. Zogenix offers a variety of prescription drugs and therapies targeting various neurological disorders and pain syndromes. The company's products aim to alleviate symptoms and address the underlying causes of the diseases. In summary, Zogenix is a biotech company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. With a wide range of products and a promising business model, the company is focused on innovation in the medical industry. Zogenix Inc represents an important area of research and development for new medications in the future. Zogenix is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Zogenix's Equity

Zogenix's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Zogenix's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Zogenix's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Zogenix's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Zogenix’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Zogenix stock

The Equity of Zogenix is 178.97 M USD in 2026.

The Equity of Zogenix changed from 369.67 M USD to 178.97 M USD, representing a -51.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Zogenix since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Zogenix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Zogenix

All Key Metrics — Zogenix